Do analysts prefer ORGS or SBFM?

Sunshine Biopharma has a consensus target price of $70.00, indicating a potential upside of 4,900.00%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Orgenesis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor ORGS or SBFM?

In the previous week, Sunshine Biopharma had 1 more articles in the media than Orgenesis. MarketBeat recorded 2 mentions for Sunshine Biopharma and 1 mentions for Orgenesis. Sunshine Biopharma's average media sentiment score of 0.87 beat Orgenesis' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orgenesis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sunshine Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SBFM or CANF?

In the previous week, Sunshine Biopharma had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 2 mentions for Sunshine Biopharma and 1 mentions for Can-Fite BioPharma. Sunshine Biopharma's average media sentiment score of 0.87 beat Can-Fite BioPharma's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sunshine Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SBFM or BPTH more profitable?

Bio-Path has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Sunshine Biopharma's return on equity of -27.75% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Sunshine Biopharma -18.45% -27.75% -21.57% Bio-Path N/A -2,842.40% -337.48%

Sunshine Biopharma (SBFM) Competitors

$1.40 +0.07 (+5.26%)

Closing price 03:58 PM Eastern

Extended Trading

$1.40 0.00 (0.00%)

As of 04:10 PM Eastern

Compare

SBFM vs. CASI, ORGS, CANF, BPTH, and ARTL

Should you buy Sunshine Biopharma stock or one of its competitors? MarketBeat compares Sunshine Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sunshine Biopharma include CASI Pharmaceuticals (CASI), Orgenesis (ORGS), Can-Fite BioPharma (CANF), Bio-Path (BPTH), and Artelo Biosciences (ARTL). These companies are all part of the "pharmaceuticals" industry.

How does Sunshine Biopharma compare to CASI Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Sunshine Biopharma has higher revenue and earnings than CASI Pharmaceuticals. Sunshine Biopharma is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Sunshine Biopharma	$36.31M	0.02	-$5.97M	-$12.90	N/A

Sunshine Biopharma has a net margin of -18.45% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Sunshine Biopharma	-18.45%	-27.75%	-21.57%

In the previous week, Sunshine Biopharma had 2 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 2 mentions for Sunshine Biopharma and 0 mentions for CASI Pharmaceuticals. Sunshine Biopharma's average media sentiment score of 0.87 beat CASI Pharmaceuticals' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Sunshine Biopharma	Positive

CASI Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Sunshine Biopharma has a consensus price target of $70.00, indicating a potential upside of 4,900.00%. Given Sunshine Biopharma's higher possible upside, analysts clearly believe Sunshine Biopharma is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Sunshine Biopharma beats CASI Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Sunshine Biopharma compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 1.9% of Orgenesis shares are held by company insiders. Comparatively, 0.5% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sunshine Biopharma has higher revenue and earnings than Orgenesis. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	2.73	-$55.36M	-$11.51	N/A
Sunshine Biopharma	$36.31M	0.02	-$5.97M	-$12.90	N/A

Sunshine Biopharma has a consensus target price of $70.00, indicating a potential upside of 4,900.00%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Orgenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sunshine Biopharma has a net margin of -18.45% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Sunshine Biopharma	-18.45%	-27.75%	-21.57%

Orgenesis has a beta of 3.14, indicating that its stock price is 214% more volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

In the previous week, Sunshine Biopharma had 1 more articles in the media than Orgenesis. MarketBeat recorded 2 mentions for Sunshine Biopharma and 1 mentions for Orgenesis. Sunshine Biopharma's average media sentiment score of 0.87 beat Orgenesis' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orgenesis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sunshine Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sunshine Biopharma beats Orgenesis on 10 of the 16 factors compared between the two stocks.

How does Sunshine Biopharma compare to Can-Fite BioPharma?

Sunshine Biopharma (NASDAQ:SBFM) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Sunshine Biopharma currently has a consensus price target of $70.00, suggesting a potential upside of 4,900.00%. Can-Fite BioPharma has a consensus price target of $44.00, suggesting a potential upside of 1,151.78%. Given Sunshine Biopharma's higher probable upside, equities research analysts plainly believe Sunshine Biopharma is more favorable than Can-Fite BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Can-Fite BioPharma has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Can-Fite BioPharma's return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-18.45%	-27.75%	-21.57%
Can-Fite BioPharma	N/A	N/A	N/A

Sunshine Biopharma has higher revenue and earnings than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.02	-$5.97M	-$12.90	N/A
Can-Fite BioPharma	$405K	5.68	-$7.63M	-$22.80	N/A

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 0.5% of Sunshine Biopharma shares are held by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Sunshine Biopharma had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 2 mentions for Sunshine Biopharma and 1 mentions for Can-Fite BioPharma. Sunshine Biopharma's average media sentiment score of 0.87 beat Can-Fite BioPharma's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sunshine Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Can-Fite BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sunshine Biopharma has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

Summary

Sunshine Biopharma beats Can-Fite BioPharma on 9 of the 16 factors compared between the two stocks.

How does Sunshine Biopharma compare to Bio-Path?

Sunshine Biopharma (NASDAQ:SBFM) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

In the previous week, Sunshine Biopharma had 2 more articles in the media than Bio-Path. MarketBeat recorded 2 mentions for Sunshine Biopharma and 0 mentions for Bio-Path. Sunshine Biopharma's average media sentiment score of 0.87 beat Bio-Path's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Sunshine Biopharma	Positive
Bio-Path	Neutral

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 0.5% of Sunshine Biopharma shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sunshine Biopharma has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.51, suggesting that its stock price is 151% less volatile than the broader market.

Sunshine Biopharma has higher revenue and earnings than Bio-Path. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.02	-$5.97M	-$12.90	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Bio-Path has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Sunshine Biopharma's return on equity of -27.75% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-18.45%	-27.75%	-21.57%
Bio-Path	N/A	-2,842.40%	-337.48%

Sunshine Biopharma currently has a consensus price target of $70.00, indicating a potential upside of 4,900.00%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Sunshine Biopharma is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Sunshine Biopharma beats Bio-Path on 11 of the 15 factors compared between the two stocks.

How does Sunshine Biopharma compare to Artelo Biosciences?

Sunshine Biopharma (NASDAQ:SBFM) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Sunshine Biopharma has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

In the previous week, Sunshine Biopharma had 2 more articles in the media than Artelo Biosciences. MarketBeat recorded 2 mentions for Sunshine Biopharma and 0 mentions for Artelo Biosciences. Sunshine Biopharma's average media sentiment score of 0.87 beat Artelo Biosciences' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Sunshine Biopharma	Positive
Artelo Biosciences	Neutral

Sunshine Biopharma has higher revenue and earnings than Artelo Biosciences. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.02	-$5.97M	-$12.90	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A

Artelo Biosciences has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Sunshine Biopharma's return on equity of -27.75% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-18.45%	-27.75%	-21.57%
Artelo Biosciences	N/A	-1,600.12%	-224.62%

Sunshine Biopharma currently has a consensus price target of $70.00, suggesting a potential upside of 4,900.00%. Artelo Biosciences has a consensus price target of $54.00, suggesting a potential upside of 7,071.31%. Given Artelo Biosciences' higher probable upside, analysts plainly believe Artelo Biosciences is more favorable than Sunshine Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 0.5% of Sunshine Biopharma shares are held by insiders. Comparatively, 3.2% of Artelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Sunshine Biopharma beats Artelo Biosciences on 11 of the 15 factors compared between the two stocks.

Get Sunshine Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBFM vs. The Competition

Export

Metric	Sunshine Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$700K	$11.78B	$6.92B	$12.85B
Dividend Yield	N/A	2.73%	2.60%	9.78%
P/E Ratio	-0.11	793.99	281.14	25.44
Price / Sales	0.02	745.63	575.40	80.57
Price / Cash	N/A	72.42	71.79	50.79
Price / Book	0.03	10.73	12.86	6.06
Net Income	-$5.97M	$2.82B	$3.49B	$348.34M
7 Day Performance	13.82%	2.79%	2.60%	3.00%
1 Month Performance	-35.78%	-1.38%	-2.67%	-3.07%
1 Year Performance	-90.00%	195.86%	75.98%	20.68%

Sunshine Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBFM Sunshine Biopharma	3.0934 of 5 stars	$1.40 +5.3%	$70.00 +4,900.0%	-90.7%	$700K	$36.31M	N/A	3	Upcoming Earnings Gap Up
CASI CASI Pharmaceuticals	N/A	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180
ORGS Orgenesis	N/A	$0.42 +5.0%	N/A	+1,809.1%	$2.17M	$662K	N/A	150	Upcoming Earnings Gap Down
CANF Can-Fite BioPharma	1.7109 of 5 stars	$3.20 +0.3%	$44.00 +1,275.0%	-76.9%	$2.10M	$405K	N/A	8
BPTH Bio-Path	N/A	$0.04 flat	N/A	-73.8%	$1.91M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBFM) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sunshine Biopharma (SBFM) Competitors

SBFM vs. CASI, ORGS, CANF, BPTH, and ARTL

How does Sunshine Biopharma compare to CASI Pharmaceuticals?

Summary

How does Sunshine Biopharma compare to Orgenesis?

Summary

How does Sunshine Biopharma compare to Can-Fite BioPharma?

Summary

How does Sunshine Biopharma compare to Bio-Path?

Summary

How does Sunshine Biopharma compare to Artelo Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sunshine Biopharma (SBFM) Competitors

SBFM vs. CASI, ORGS, CANF, BPTH, and ARTL

How does Sunshine Biopharma compare to CASI Pharmaceuticals?

Do insiders & institutionals have more ownership in CASI or SBFM?

Which has more volatility & risk, CASI or SBFM?

Which has preferable valuation & earnings, CASI or SBFM?

Is CASI or SBFM more profitable?

Does the media favor CASI or SBFM?

Do analysts recommend CASI or SBFM?

Summary

How does Sunshine Biopharma compare to Orgenesis?

Do insiders & institutionals believe in ORGS or SBFM?

Which has preferable earnings & valuation, ORGS or SBFM?

Do analysts prefer ORGS or SBFM?

Is ORGS or SBFM more profitable?

Which has more risk & volatility, ORGS or SBFM?

Does the media favor ORGS or SBFM?

Summary

How does Sunshine Biopharma compare to Can-Fite BioPharma?

Do analysts recommend SBFM or CANF?

Is SBFM or CANF more profitable?

Which has better earnings and valuation, SBFM or CANF?

Do insiders & institutionals hold more shares of SBFM or CANF?

Does the media refer more to SBFM or CANF?

Which has more risk and volatility, SBFM or CANF?

Summary

How does Sunshine Biopharma compare to Bio-Path?

Does the media favor SBFM or BPTH?

Do institutionals and insiders have more ownership in SBFM or BPTH?

Which has more volatility & risk, SBFM or BPTH?

Which has better earnings & valuation, SBFM or BPTH?

Is SBFM or BPTH more profitable?

Do analysts rate SBFM or BPTH?

Summary

How does Sunshine Biopharma compare to Artelo Biosciences?

Which has more volatility & risk, SBFM or ARTL?

Does the media favor SBFM or ARTL?

Which has better valuation and earnings, SBFM or ARTL?

Is SBFM or ARTL more profitable?

Do analysts recommend SBFM or ARTL?

Do insiders and institutionals hold more shares of SBFM or ARTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools